- Innovating sustainable crop protection products through leading edge discovery, development and delivery methods.
- Acidophil co-founded Agrimetis in 2014 with a series A raise of $10M.
- At the beginning of 2017, AgriMetis raised $23.5M Series B capital.
- PGT developed and patented biochemical processes and analytical tools that enable a better understanding and practical application of the inherent complexity of human, animal, plant and microbiological genomes.
- PGT was formed by seed investments from the Wellcome Trust and Compass Genetics (the Acidophil affiliate) and to date PGT has raised a total £13.4 million including additional investment from the original investors as well as from Auriga Partners, Beringea and Syngenta Ventures.
- PGT, with Acidophil’s help, is in the process of commercializing its technology and providing value to its investors by selling its intellectual property to life science research tool and molecular diagnostics companies.
- Cost-competitive solutions to produce renewable intermediate chemicals via a bio-based or a fully biological approach using any one of a number of specifically tailored microorganisms that can utilise low cost feedstocks.
- ZuvaChem merged with BioSyntha to form ZuvaSyntha in 2015
- Since the merger, Acidophil has provided advice to ZuvaSyntha through board participation
- Arginetix (later Corridor Pharmaceuticals) was formed to develop therapeutics arginase inhibitors to treat respiratory and cardiac indications.
- Arginetix raised $2 million seed funds from Acidophil, MedImmune Ventures and Quaker BioVentures and Red Abbey Venture Partners, then attracted a $7 million Series A financing.
- Arginetix merged with Immune Control to form Corridor Pharmaceuticals, which was subsequently acquired by AstraZeneca.